This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Neurology				
Alzheimer's disease (AD)	Microtubule-associated protein- τ (MAPT; TAU; FTDP-17); β -amyloid 42 (A β 42)	<p>Studies of cerebrospinal fluid samples identified biomarkers that could help predict development of AD. In protein assays of cerebrospinal fluid samples from patients with mild cognitive impairment, lower median Aβ42 and higher phosphorylated TAU and total TAU levels occurred in patients who later developed AD compared with those who did not. Next steps include using the biomarkers to detect patient response to AD therapeutics.</p> <p>EnVivo Pharmaceuticals Inc. has EVP-0962, which targets Aβ42, in preclinical testing to treat AD.</p> <p>SciBX 2(29); doi:10.1038/scibx.2009.1157 Published online July 30, 2009</p>	Patent and licensing status not applicable	<p>Mattsson, N. <i>et al.</i> <i>JAMA</i>; published online July 21, 2009; doi:10.1001/jama.2009.1064</p> <p>Contact: Niklas Mattsson, Sahlgrenska University Hospital/Molndal, Molndal, Sweden e-mail: niklas.mattsson@neuro.gu.se</p>